Covid-19 Tanısı alan hastalarda tedavi ve klinik deneyimler

İ. Yildiz, İlkay Bahçeci̇
{"title":"Covid-19 Tanısı alan hastalarda tedavi ve klinik deneyimler","authors":"İ. Yildiz, İlkay Bahçeci̇","doi":"10.38175/phnx.1240296","DOIUrl":null,"url":null,"abstract":"Purpose : All over the world, a specific antiviral and immunomodulatory treatment method that can affect COVID-19 infection has not been found, and research is ongoing. Our goal is to share our clinical experience in patients receiving in patient treatment in our clinic. \nMaterials and Methods: Patients whose symptoms were compatible with COVID-19 and whose microbiological findings and/ortomography findings were compatible between March 11 and May 31, 2020 were included in the study. \nResults: Among 180 patients included in the study; It was found that favipiravir treatment was added to 45 (25.0%) patients after HCQ treatment. A significant difference was found between treatment groups concerning; age, occupation, oxygen saturation, presence of Diabetes Mellitus, Hypertansion and lung disease, and CT findings (p","PeriodicalId":134281,"journal":{"name":"Phoenix Medical Journal","volume":"178 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phoenix Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.38175/phnx.1240296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose : All over the world, a specific antiviral and immunomodulatory treatment method that can affect COVID-19 infection has not been found, and research is ongoing. Our goal is to share our clinical experience in patients receiving in patient treatment in our clinic. Materials and Methods: Patients whose symptoms were compatible with COVID-19 and whose microbiological findings and/ortomography findings were compatible between March 11 and May 31, 2020 were included in the study. Results: Among 180 patients included in the study; It was found that favipiravir treatment was added to 45 (25.0%) patients after HCQ treatment. A significant difference was found between treatment groups concerning; age, occupation, oxygen saturation, presence of Diabetes Mellitus, Hypertansion and lung disease, and CT findings (p
目的:在全球范围内,尚未找到能够影响COVID-19感染的特异性抗病毒和免疫调节治疗方法,研究正在进行中。我们的目标是与在我们诊所接受治疗的患者分享我们的临床经验。材料和方法:纳入2020年3月11日至5月31日期间症状与COVID-19相符且微生物学和/或断层扫描结果相符的患者。结果:纳入研究的180例患者中;在HCQ治疗后,有45例(25.0%)患者加用favipiravir治疗。治疗组之间存在显著差异:年龄、职业、血氧饱和度、有无糖尿病、高血压和肺部疾病,以及CT表现(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信